ZyVersa Therapeutics, Inc.
ZVSA
$0.7899
-$0.0111-1.39%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 1.83M | 2.04M | 2.31M | 1.52M | 2.23M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 2.27M | 2.75M | 2.83M | 1.78M | 2.90M |
Operating Income | -2.27M | -2.75M | -2.83M | -1.78M | -2.90M |
Income Before Tax | -2.40M | -2.75M | -2.83M | -13.93M | -2.90M |
Income Tax Expenses | -- | 9.70K | -- | -596.10K | -500.00 |
Earnings from Continuing Operations | -2.40M | -2.76M | -2.83M | -13.34M | -2.90M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -2.40M | -2.76M | -2.83M | -13.34M | -2.90M |
EBIT | -2.27M | -2.75M | -2.83M | -1.78M | -2.90M |
EBITDA | -2.27M | -2.75M | -2.82M | -1.77M | -2.90M |
EPS Basic | -2.43 | -3.31 | -4.53 | -59.63 | -30.18 |
Normalized Basic EPS | -1.52 | -2.06 | -2.83 | -4.96 | -18.66 |
EPS Diluted | -2.43 | -3.31 | -4.53 | -59.63 | -30.18 |
Normalized Diluted EPS | -1.52 | -2.06 | -2.83 | -4.96 | -18.66 |
Average Basic Shares Outstanding | 988.40K | 834.90K | 623.60K | 223.70K | 97.30K |
Average Diluted Shares Outstanding | 988.40K | 834.90K | 623.60K | 223.70K | 97.30K |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |